Bibiana Castagna Mota

Bibiana Castagna Mota

Auto-generated profile, based on publicly available information

Bibiana Castagna Mota

Department of Brain Sciences, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Brain
Verified
Journal Article
Open access
PDF file
MRMiriam Ries
Miriam Ries
HWHelena Watts
Helena Watts
BMBibiana C Mota
Bibiana C Mota
MLMaria Yanez Lopez
Maria Yanez Lopez
CDCornelius K Donat
Cornelius K Donat
MSMagdalena Sastre
Magdalena Sastre
Alzheimer’s disease, characterized by brain deposits of amyloid-β plaques and neurofibrillary tangles, is also linked to neurovascular dysfunction and blood–brain barrier breakdown, affecting the passage of substances into and out of the brain. We hypothesized that treatment of neurovascular alterations could be beneficial in Alzheimer’s disease. Annexin A1 (ANXA1) is a mediator of glucocorticoid anti-inflammatory action that can suppress microglial activation and reduce blood–brain barrier leakage. We have reported recently that treatment with recombinant human ANXA1 (hrANXA1) reduced amyloid-β levels by increased degradation in neuroblastoma cells and phagocytosis by microglia. Here, we show the beneficial effects of hrANXA1 in vivo by restoring efficient blood–brain barrier function and decreasing amyloid-β and tau pathology in 5xFAD mice and Tau-P301L mice. We demonstrate that young 5xFAD mice already suffer cerebrovascular damage, while acute pre-administration of hrANXA1 rescued the vascular defects. Interestingly, the ameliorated blood–brain barrier permeability in young 5xFAD mice by hrANXA1 correlated with reduced brain amyloid-β load, due to increased clearance and degradation of amyloid-β by insulin degrading enzyme (IDE). The systemic anti-inflammatory properties of hrANXA1 were also observed in 5xFAD mice, increasing IL-10 and reducing TNF-α expression. Additionally, the prolonged treatment with hrANXA1 reduced the memory deficits and increased synaptic density in young 5xFAD mice. Similarly, in Tau-P301L mice, acute hrANXA1 administration restored vascular architecture integrity, affecting the distribution of tight junctions, and reduced tau phosphorylation. The combined data support the hypothesis that blood–brain barrier breakdown early in Alzheimer’s disease can be restored by hrANXA1 as a potential therapeutic approach.

Verified
Journal Article
Open access
PDF file
BMBibiana C. Mota
Bibiana C. Mota
MSMagdalena Sastre
Magdalena Sastre
The peroxisome proliferator-activated receptor co-activator-1α (PGC1α) belongs to a family of transcriptional regulators, which act as co-activators for a number of transcription factors, including PPARs, NRFs, oestrogen receptors, etc. PGC1α has been implicated in the control of mitochondrial biogenesis, the regulation of the synthesis of ROS and inflammatory cytokines, as well as genes controlling metabolic processes. The levels of PGC1α have been shown to be altered in neurodegenerative disorders. In the brains of Alzheimer’s disease (AD) patients and animal models of amyloidosis, PGC1α expression was reduced compared with healthy individuals. Recently, it was shown that overexpression of PGC1α resulted in reduced amyloid-β (Aβ) generation, particularly by regulating the expression of BACE1, the rate-limiting enzyme involved in the production of Aβ. These results provide evidence pointing toward PGC1α activation as a new therapeutic avenue for AD, which has been supported by the promising observations of treatments with drugs that enhance the expression of PGC1α and gene therapy studies in animal models of AD. This review summarizes the different ways and mechanisms whereby PGC1α can be neuroprotective in AD and the pre-clinical treatments that have been explored so far.

Verified
Journal Article
Open access
PDF file
BMBibiana C. Mota
Bibiana C. Mota
NANathan Ashburner
Nathan Ashburner
LALaura Abelleira-Hervas
Laura Abelleira-Hervas
LLLiyueyue Liu
Liyueyue Liu
RARobertas Aleksynas
Robertas Aleksynas
MSMagdalena Sastre
Magdalena Sastre
Recent evidence suggests that I2-imidazoline ligands have neuroprotective properties in animal models of neurodegeneration, such as Alzheimer’s disease (AD). We recently demonstrated that the I2-ligand BU224 reversed memory impairments in AD transgenic mice and this effect was not because of reductions in amyloid-β (Aβ) deposition. In this study, our aim was to determine the therapeutic potential of the powerful analgesic I2-imidazoline ligand CR4056 in the 5xFAD model of AD, since this ligand has been proven to be safely tolerated in humans. Sub-chronic oral administration of CR4056 (30 mg/kg for 10 days) led to an improvement in recognition memory in 6-month-old 5xFAD mice, but not in wild-type littermates, without affecting Aβ levels or deposition. Our results also revealed a change in the profile of microglia by CR4056, resulting in a suppression of pro-inflammatory activated microglia, but increased the density of astrocytes and the expression of ApoE, which is mainly produced by these glial cells. In addition, CR4056 restored fibrinogen extravasation, affecting the distribution of markers of astrocytic end feet in blood vessels. Therefore, these results suggest that CR4056 protects against Aβ-mediated neuroinflammation and vascular damage, and offers therapeutic potential at any stage of AD.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
BMBibiana Castagna Mota
Bibiana Castagna Mota
EAElisavet Velentza Almpani
Elisavet Velentza Almpani
MNMARIA NIKOLAOU
MARIA NIKOLAOU
MGMonica Emili Garcia‐Segura
Monica Emili Garcia‐Segura
YHYu‐Hsuan Huang
Yu‐Hsuan Huang
MSMagdalena Sastre
Magdalena Sastre
Background: Alzheimer’s disease (AD) is the most prevalent form of dementia in the elderly. AD has no cure but symptomatic treatment, thus, an effective therapy is urgently needed. Previously in our laboratory we have explored the potential neuroprotective effects of the coactivator for the peroxisome proliferator‐activated receptor‐γ (PPARγ), ‐PGC‐1α mainly involved in the regulation of metabolic processes and mitochondrial biogenesis. PGC‐1α has been shown to be involved in different neurodegenerative diseases and its expression is reduced in the brain of AD patients. We have previously showed that the delivery of PGC‐1α through lentiviral vectors in APP23 mice, at the preclinical stage of the disease, resulted in reduction of amyloid‐β deposition, protection against neuronal loss and improvement of cognition functions. Therefore, the aim of this study was to generate a monocistronic lentiviral vector expressing PGC‐1α to investigate whether this therapy could ameliorate the cognitive deficit ofAPP23 mouse model of AD at an advanced stage of pathology.Method: A recombinant lentiviral vector carrying human codon optimized PGC‐1αdriven by CMV promoter was constructed and produced. To determine the therapeutic effects of overexpression of PGC‐1α, we delivered the lentiviral vector carrying PGC‐1α in the frontal cortex and hippocampus of wildtype and APP23 mice at 12 months old and animals were sacrificed 3 months later. We investigated locomotor activity and anxiety (Open Field, OF), non‐spatial (Novel Object Recognition, NOR) and spatial memories (Object Location test, OLT).Result: So far, no differences were observed in the anxiety and locomotor activity between the groups in the OF test. APP23 mice at 15 months of age showed cognitive impairment compared with controls. Interestingly, improvement in the performance in the NOR test was observed in the APP23 mice injected with PGC‐1α vector (p>0.05, two‐way ANOVA, Bonferroni post‐hoc, n=5‐10 per group). However, in the OLT test no difference was observed between the groups 3 months after the PGC‐1α delivery.Conclusion: These preliminary results support the potential therapeutic effect of PGC1alpha on cognition at late stages of the disease.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
RARobertas Aleksynas
Robertas Aleksynas
BMBibiana Castagna Mota
Bibiana Castagna Mota
LCLuis Callado
Luis Callado
MSMagdalena Sastre
Magdalena Sastre
Background: Major depressive disorder (MDD) is linked with a 2‐fold higher risk of developing Alzheimer’s disease (AD), yet the mechanisms behind this association are unclear and are confounded by psychotropic drug use. We, therefore, aimed to investigate AD‐related transcriptional changes in post‐mortem MDD brains without symptoms of dementia and their matched controls, taking into consideration psychotropic medication‐use history.Method: NanoString Technologies nCounter® analysis using their Alzheimer’s Disease Panel (770 genes) was performed on mRNA extracts from post‐mortem prefrontal cortex tissue of suicide victims with ante‐mortem MDD diagnoses, including 6 drug‐free cases and 6 with a previous history of psychotropic medication use whose serological screening included antidepressants, antipsychotics, benzodiazepines. The results were compared with 12 age and sex matched non‐neurological controls. The data was analysed using nSolver advanced analysis software and built‐in statistical analyses.Result: When comparing total MDD cases vs. healthy controls, genes involved in lipid metabolism and myelination (e.g., CDK18, 1.9‐fold; ABCA2, 1.91) and cytokines (CSF1, 1.93; LIFR, 1.26) were found upregulated in MDD, whereas the most downregulated genes included neurotransmitter synthesis and storage (RAB3A, 0.79), neurotransmitter release (CAMK4, 0.741) and vesicle trafficking (NPTX2, 0.519). In a comparison of MDD drug‐free group vs. MDD with drug use group, patients with drug use displayed upregulations of genes related to lipid metabolism and myelination (NKX6‐2, 4.5) autophagy (ABCA2, 3.32) and cytokines (CSF1, 2.53; LIFR 1.34), whereas drug‐free patients showed higher expression of neurotransmitter release (GRIA3, 0.742), transcription‐splicing (DDX42, 0.807) and trophic factor (NTRK2, 0.732) genes. TSPO, a gene related to microglial activation, was the most significantly upregulated gene (3.23‐fold) in MDD patients taking psychotropic medications.Conclusion: The study provides evidence that alterations in pathways involving neuroinflammation, metabolism and neurotransmission in the brains of MDD patients might provide the link with AD and highlights the need to investigate the role of psychotropic medications in modulating AD‐related pathways.